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(P0) to P10; the majority of immunostained cells were inner 
hair cells, outer hair cells, and supporting cells. Finally, a peak 
in the mRNA and protein expression of both receptors is 
present near the time when they respond to physiological 
hearing (i.e., hearing of airborne sound) at P14. At P21, SSTR1 
and SSTR2 levels decrease dramatically. A similar develop-
mental pattern was observed for SSTR1 and SSTR2 mRNA, 
suggesting that the expression of the SSTR1 and SSTR2 
genes is controlled at the transcriptional level throughout 
development. In addition, we observed reduced levels of 
phospho-Akt and total Akt in SSTR1 knockout and SSTR1/
SSTR2 double-knockout mice compared with wild-type 
mice. We know from previous studies that Akt is involved
in hair cell survival. Taken together, the dynamic nature of 
SSTR1 and SSTR2 expression at a time of major developmen-
tal changes in the cochlea suggests that SSTR1 and SSTR2 
(and possibly other members of this family) are involved in 
the maturation of the mammalian cochlea. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Hearing loss is a global health problem with a pro-
found socioeconomic impact. Acquired hearing loss is 
mainly a modern disorder caused by (among other things) 
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 Abstract 
 The neuropeptide somatostatin (SST) exerts several impor-
tant physiological actions in the adult central nervous sys-
tem through interactions with membrane-bound receptors. 
Transient expression of SST and its receptors has been de-
scribed in several brain areas during early ontogeny. It is 
therefore believed that SST may play a role in neural matura-
tion. The present study provides the first evidence for the 
developmental expression of SST receptors in the mamma-
lian cochlea, emphasizing their possible roles in cochlear 
maturation. In the developing mouse cochlea, cells immuno-
reactive to somatostatin receptor 1 (SSTR1) and somatostatin 
receptor 2 (SSTR2) were located in the embryonic cochlear 
duct on Kolliker’s organ as early as embryonic day (E) 14 (E14). 
At E17, the expression of both receptors was high and already 
located at the hair cells and supporting cells along the length 
of the cochlear duct, which have become arranged into the 
characteristic pattern for the organ of Corti (OC) at this stage. 
At birth, SSTR1- and SSTR2-containing cells were only local-
ized in the OC. In general, immunoreactivity for both recep-
tors increased in the mouse cochlea from postnatal day (P) 0 
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human-made noise and modern drugs. These factors, 
combined with increasing lifespan, have exposed a deficit 
in cochlear self-regeneration that had been irrelevant 
throughout most of mammalian evolution. The mamma-
lian inner ear is an unusually complex organ that con-
tains both vestibular and auditory parts. The vestibular 
sensory organs are necessary for the maintenance of nor-
mal balance. The coiled cochlea which contains the organ 
of Corti (OC) consists of four parallel rows of sensory hair 
cells (HCs) along the longitudinal axis of the spiraled co-
chlea. The first row of HCs from the center (or medial 
side) of the cochlea is known as inner hair cells (IHCs). 
The remaining three rows of HCs toward the periphery 
(or lateral side) of the cochlea are known as outer HCs. 
Invariably, HCs are separated from each other by several 
types of morphologically distinct nonsensory supporting 
cells, including Deiter’s cells (DC), Claudius cells, 
Boettcher cells, and pillar cells (PiC). Supporting cells 
share a common progenitor with HCs  [1] , and are a mor-
phologically diverse population of epithelial cells that 
surround HCs and provide structural and functional 
support. In mice, the cochlear duct arises as a ventral 
evagination of the developing otocyst beginning at ap-
proximately embryonic day (E) 11 (E11)  [2] . The duct it-
self is comprised of pseudostratified epithelial cells de-
rived from the otic placode. By E12, the chirality of the 
growing duct becomes obvious as it begins to coil. During 
development, the precursor cells give rise to both sensory 
HCs and the formation of supporting cells. These precur-
sor cells, which transiently form Kolliker’s organ (KlO) in 
the OC, exit the cell cycle at approximately E14. By E17, 
HCs and supporting cells have become arrayed along the 
length of the cochlear duct. Gross anatomical changes of 
the inner ear have been correlated with the appearance of 
each sensory organ. In turn, the appearance of each organ 
has been identified by the observation of specific gene 
expression in sensory regions before histological differ-
entiation. The Notch signaling pathway has multiple 
roles during inner ear development  [3, 4] . Notch signaling 
activates the transcription of Hes5, a homologue of  Dro-
sophila  hairy and enhancer of split proteins, which en-
codes a basic helix-loop-helix transcriptional repressor. 
Previous studies have shown that Hes5 is expressed in the 
cochlea during embryonic development  [5–7] .
 Somatostatin (SST), a regulatory peptide with two bio-
active forms, SST-14 and SST-28, is produced in neuroen-
docrine cells in the brain and periphery and acts on a 
wide array of tissue targets to modulate neurotransmis-
sion, cell secretion, and cell proliferation  [8, 9] . The ac-
tions of SST are mediated by a family of G protein-cou-
pled receptors with five subtypes (SST receptors 1–5, 
SSTR1–5) encoded by separate genes  [8, 10] . SSTR couple 
to the voltage-dependent Ca 2+ channels and mediate the 
inhibition of Ca 2+ conductance by SST. Cloned SSTR2 
has been reported to inhibit Ca 2+ conductance when ex-
pressed in RINm5F cells  [11] . SSTR have also been re-
ported to couple to Ca 2+ -dependent K + channels and me-
diate increases in K + conductance  [12] . The modulation 
of ionic conductance may be an underlying mechanism 
by which SST inhibits neuronal cell firing and reduces 
neurotransmitters and hormone secretion.
 Studies over the last few years in mice show that SST 
and its receptors appear to play an important role in cell 
death. In a retina ischemia model, activation of the SSTR2 
protected retinal neurons from damage  [13] . In the pitu-
itary tumor cells the octreotid, a SST analogue, mediates 
its antiproliferative action by altering phosphatidylinosi-
tol-3-kinase (PI3K)-Akt signaling  [14] . Also in neuroen-
docrine tumors octreotid decreases PI3K-Akt signaling 
 [15] . Dying HCs after ototoxic and acoustic trauma ex-
hibit apoptotic morphology, suggesting that apoptosis is 
involved in HC death. Inhibition of apoptotic HC death 
can be manipulated by blocking of caspase family and the 
MAPK-JNK pathway  [16] . We have demonstrated recent-
ly that the PI3K-Akt pathway is involved in NF-  B-de-
pendent HC survival. Most importantly, we found im-
proved HC survival in SST-treated OC explants that had 
been exposed to gentamicin compared to those explants 
exposed to gentamicin alone  [17] . Therefore, it might be 
possible that SST also exerts its effect on HCs through the 
PI3K-Akt survival pathway.
 SST is a potential candidate for influencing early neu-
ronal development, since the neuropeptide is transiently 
expressed in several neuronal systems. A variety of stud-
ies support a developmental role for SST by documenting 
its early onset, transient expression, and morphogenetic 
effects  [18, 19] . Transient expression of SST protein or 
mRNA has been described in the cerebellum  [20] , the ce-
rebral cortex  [21] , and in sensory systems, including the 
somatosensory, visual  [22] , and auditory systems  [23] . Re-
cent studies have shown that SST exerts some regulatory 
effects during neuronal maturation, as it has been report-
ed that SST enhances neurite outgrowth in cultured cer-
ebellar neurons  [24] .
 In prenatal brain neurons, SST and its receptors are 
expressed early and transiently; however, little is known 
about their function during early mammalian cochlear 
development. Our previous study demonstrated that 
SSTR1 and SSTR2 mRNA and protein were expressed in 
the adult mouse cochlea, and were localized in the IHC, 
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outer hair cells (OHC), and supporting cells of the OC 
 [25] . SSTR3, 4, and 5 have not been shown to be essential 
for the function of SST  [10] . Therefore, we focused our 
attention on the distributions of SSTR1 and SSTR2. Our 
examinations focused on E14, E17, and the first 3 postna-
tal weeks, when important steps of cochlear and synapse 
maturation occur and hearing begins  [26–28] . In this 
study, we investigated the expression patterns of SSTR1 
and SSTR2 in the cochlea of the developing mouse, and 
correlated it with developmental events. The expression 
levels of SSTR1 and SSTR2 in mouse cochlea between E14 
and postnatal day (P) 21 (P21) were assessed at the mRNA 
and protein levels. Morphological studies were also con-
ducted. In this study, SSTR1/SSTR2 double-knockout 
(DKO) mice were generated to determine the importance 
of these receptors because there are compensatory effects 
in the single knockouts (KO) and the phenotype of the 
DKO has not been characterized previously.
 Finally, we analyzed the expression levels of phospho-
Akt and total Akt in wild-type (WT), SSTR1 KO, and 
SSTR1/SSTR2 DKO mice.
 Material and Methods 
 Animals 
 Experiments were performed on mouse cochleae from WT 
C57BL/6 mice of both sexes. The expression of both receptors was 
detected in mice at embryonic stages (n = 10 per embryonic day 
for mRNA isolation; n = 10 per embryonic day for protein isola-
tion; n = 4 per embryonic day for immunohistochemistry). The 
patterns of SSTR1 and SSTR2 expression were also observed at 
postnatal ages (n = 10 per postnatal day for mRNA isolation; n = 
10 per postnatal day for protein isolation). Immunohistochemis-
try was performed on 4 mice per postnatal day). The procedures 
used to generate SSTR1 –/– (homozygous SSTR1 KO)/C57BL6J 
mice  [29] and SSTR2 –/– (homozygous SSTR2 KO)/C57BL6J mice 
have been described previously  [30] . SSTR1 KO mice were crossed 
with SSTR2 KO mice to produce DKO mice. Age-matched WT 
mice were produced from the C57BL6J mice that were used to 
stabilize the genetic backgrounds of the SSTR1 KO and SSTR2 KO 
mice. The SSTR1/SSTR2 DKO showed no apparent abnormali-
ties. They reproduced normally with a litter size of 6–10 animals. 
When homozygous animals were compared with their WT litter-
mates no obvious abnormalities were detected. No differences in 
the body weight of adult animals were observed. Upon dissection 
of adult animals internal organs were found to be of normal size 
and shape. We tested the hearing of DKO mice using brainstem 
electric-response audiometry. We tested age-matched DKO, WT, 
and SST1 KO mice (n = 15 mice per group) 3 times at approxi-
mately 3 months of age. Compared with WT and SST1 KO mice, 
SSTR1/SSTR2 DKO mice exhibited hearing impairment [unpubl. 
observation].
 Animal care and use were conducted in conformity with the 
European Communities Council Directive of 24 November 1986 
(86/609/EEC), and were reviewed and permitted by the Kanto-
nales Veterinäramt, Basel, Switzerland.
 RNA Extraction 
 The OCs from WT mouse pups aged E14–P21 were later placed 
separately in RNA (Qiagen, Hombrechtikon, Switzerland). RNA 
isolation of the brains and the inner ear components was per-
formed using the RNAeasy Minikit (Qiagen) and employing an 
Ultra-Turrax T8 tissue homogenizer (IKA-Werke, Staufen, Ger-
many) according to the manufacturer’s instructions, including 
DNAse treatment. The quantity and quality of isolated RNA were 
determined with NanoDrop ND 1000 (NanoDrop Technologies, 
Wilmington, Del., USA). The 260/280-nm ratio of all samples was 
between 1.8 and 2.1.
 Reverse Transcription Polymerase Chain Reaction 
 Total RNA (500 ng) was reverse transcribed into cDNA with 
the first-strand cDNA synthesis kit for reverse transcription poly-
merase chain reaction (RT-PCR; Roche Applied Bioscience, Rot-
kreuz, Switzerland) according to the supplier’s instructions. PCR 
was performed using the PCR Master Mix (Roche Applied Biosci-
ence) with primers specific for SSTR1 and SSTR2.   -Actin prim-
ers were used as a positive control for cDNA synthesis. Primers 
were designed to cross at least one exon junction for the specific 
amplification of cDNA and to recognize genomic DNA contami-
nation. The primer sequences were: SSTR1 forward (fwd): 5  -
CAGGGTAGCGCCATTCTCATC-3  , SSTR1 reverse (rev): 5  -
AGCGTGGAAGTGACCAGAAAG-3  , SSTR2 fwd: 5  -CGCATG-
GTGTCCATCGTAGT-3  , SSTR2 rev: 5  -GGATTGTGAATTG-
TCTGCCTTGA-3  ,   -actin fwd: 5  -ACGGTCAGGTCATCAC-
TATCGGCA-3  , and   -actin rev: 5  -ATCCTGTCAGCAATGC-
CTGGGT-3  (Microsynth, St. Gallen, Switzerland).
 PCR reactions were performed in the Eppendorf Mastercycler 
(Eppendorf, Hamburg, Germany). For SSTR1 and SSTR2, the ini-
tial denaturing step (94  °  C for 30 s) was followed by 30 PCR cycles, 
each consisting of denaturation at 94   °   C for 15 s, annealing at 
60  °  C for 30 s, and extension at 72  °  C for 15 s. PCR was completed 
with a final extension step at 72   °   C for 3 min.   -Actin was sub-
jected to 30 PCR cycles, each consisting of denaturation at 94  °   C 
for 30 s, annealing at 58   °   C for 45 s, and extension at 72   °   C for
90 s. PCR was completed with a final extension step at 72° for
5 min. The PCR products were stained with SybrGreen I (Mo-
lecular Probes, Eugene, Oreg., USA), separated by electrophoresis 
on a 2% agarose gel, and visualized under ultraviolet light. Omis-
sion of RT-PCR was used as the no-template control.
 Real-Time PCR 
 Total RNA (500 ng) was reverse transcribed into cDNA using 
the First Strand cDNA synthesis kit (Roche Applied Biosciences) 
according to the manufacturer’s instructions. The reaction took 
place in an ABI Prism 7900HT Sequence Detection System (Ap-
plied Biosystems) using a Fast Start Universal SYBR Green Master 
(Rox) (Roche Applied Biosciences, Foster City, Calif., USA). The 
primer sequences were: SSTR1 fwd: 5  -CAGGTTTAAAGAAC-
TGGCAAGC-3  , SSTR1 rev: 5  -ATTAATAAGCGGCACCATCG-
3  , SSTR2 fwd: 5  -TCTTTGCTTGGTCAAGGTGA-3  , and SSTR2 
rev: 5  -TCCTGCTTACTGTCGCTCCT-3  (Microsynth). Each re-
action contained 300 n M of primer. The cycling parameters were 
10 min at 95   °   C, followed by 40 cycles of 95   °   C for 15 s and 60   °   C 
for 60 s. We calculated relative quantities of specifically amplified 
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cDNA using the comparative threshold cycle method. GAPDH 
was used as an endogenous reference (Microsynth). Template-free 
and reverse-transcription-free controls ensured that nonspecific 
amplification and DNA contamination could be excluded.
 Preparation of Paraffin Cochlear Sections 
 Mice were killed with an overdose of sodium pentobarbital 
(100 mg/kg) and transcardially perfused with 50 ml of phosphate-
buffered 4% paraformaldehyde (pH 7.4, at 4  °  C). The inner ear was 
carefully removed. Decalcification was carried out in a light-pro-
tected flask for 10 days in a solution of 120 m M EDTA (Merck, 
Whitehouse Station, N.J., USA) in distilled water (pH 6.8). After 
decalcification, cochleae were prepared for paraffin embedding. 
Briefly, cochleae were dehydrated in graded ethanol solutions (at 
70, 80, 95%, and 3  ! 100%, each for 1 h; 3 ! xylol for 1 h; 2 ! 
paraplast at –60   °   C for 1 h, and paraplast at –60   °   C for 10 h), and 
embedded in paraffin at 56  °  C.
 Histology and Immunocytochemistry 
 For histological evaluation, cochlear sections of 10   m thick-
ness were cut on a Leitz microtome and mounted on Superfrost 
plus slides (Menzel, Braunschweig, Germany). Sections were depa-
raffinized, rehydrated, washed in PBS for 5 min, and subjected to 
immunohistochemistry. For histological evaluation of the brain, 
coronal sections of 30-mm thickness were collected and mounted 
on Superfrost Plus slides (Menzel) and dried at room temperature. 
Microtome sections of mouse cochlea were incubated for 1 h at 
room temperature in blocking solution (PBS-T) containing 5% Tri-
ton X-100 (pH 8) and 3% normal goat serum (NGS). The sections 
were incubated with primary antibody diluted in PBS-T with 1% 
NGS overnight at 4   °   C. The following primary antibodies were 
used: rabbit polyclonal anti-SSTR1 and anti-SSTR2 antibodies (1: 
 400, Gramsch Laboratories, Schwabhausen, Germany) and mouse 
monoclonal anti-Hes5 antibody (1: 300, AbCam, Cambridge, UK). 
After 3 washes in PBS-T, the sections were incubated for 1 h at room 
temperature with the appropriate secondary antibodies (1: 250, Al-
exa-conjugated, Molecular Probes, LuBioScience, Lucerne, Swit-
zerland) diluted in PBS-T with 1% NGS for 2 h at room tempera-
ture. After washing in PBS, the sections were counterstained with 
DAPI and mounted on glass slides with Mowiol.
 Slices were visualized on an Olympus AX-70 microscope 
equipped with a spot digital camera. Recorded images were ad-
justed for brightness and contrast using Image-Pro Plus and Pho-
toshop image processing software.
 Confocal Microscopy 
 The paraffin sections were analyzed using a confocal laser 
scanning microscope (TCS5D, Leica Microsystems, Mannheim, 
Germany) equipped with multiple laser line excitation (405, 458, 
488, 514, 561, and 633 nm), acustooptical devices (AOTF and 
AOBF modules), and operated in the simultaneous acquisition 
mode. Images were recorded with an apochromatic 60 ! /nA 1.4 
objective lens. Image stacks of 15–25 optical layers were sampled 
according to the Nyquist theorem. Subsequently, the stacks of im-
ages were displayed using the Imaris software package (Bitplane 
AG, Zürich, Switzerland).
 Western Blotting 
 Animals were decapitated and cochleae were carefully micro-
dissected in ice-cold PBS. The OC was separated from the spiral 
ganglion and the stria vascularis. Brain extract was used as a pos-
itive control. Explants were homogenized in CelLytic buffer con-
taining protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Mo., 
USA) and centrifuged. Supernatants were aspirated and placed in 
a new tube. Protein concentration was determined using the BCA 
Protein Assay Reagent kit (Pierce, Rockford, Ill., USA) according 
to the manufacturer’s instructions. Lysates were mixed with 
Laemmli sample buffer and heated at 95   °   C for 5 min. A 20-  g 
sample of each lysate was resolved on a 10% SDS-PAGE gel and 
blotted onto a polyvinylidene fluoride membrane. The nonspe-
cific sites of the transferred proteins were blocked with blocking 
solution (Roche, Switzerland) diluted (1: 100) in PBS-T (1.54 m M 
KH 2 PO 4 ; 155.17 m M NaCl; 2.71 m M Na 2 HPO 4  7H 2 O, pH 7.2; 
0.1% Tween 20) for 1 h at room temperature. The membrane was 
washed with PBS-T (3  ! 10 min) and then incubated with pri-
mary antibodies in TBS. The following primary antibodies were 
used: rabbit polyclonal anti-SSTR1 and anti-SSTR2 (1: 1,000, Ab-
cam, UK), rabbit polyclonal anti-Akt (1: 1,000, Cell Signaling, 
Switzerland), rabbit polyclonal anti-phospho-Akt (1: 1,000, Cell 
Signaling, Switzerland), and mouse monoclonal anti-  -actin
(1: 5,000, Santa Cruz Biotech, Santa Cruz, Calif., USA). The mem-
branes were incubated with the primary antibodies overnight at 
4  °  C. Next, the blots were incubated with monoclonal anti-rabbit 
peroxidase-conjugated secondary antibody (1: 80,000; Sigma-Ald-
rich, St. Gallen, Switzerland) and anti-mouse peroxidase-conju-
gated secondary antibody (1: 200,000; Sigma-Aldrich).
 The blots were washed with PBS-T (3  ! 10 min) and incu-
bated with appropriate peroxidase-conjugated secondary anti-
body for 1 h at room temperature (Roche, Basel, Switzerland). 
After washing, bands were visualized using BM chemilumines-
cence developmental solution (Roche). The immunopositive 
bands were visualized by autoradiograpy. Serial exposures were 
made to radiographic film (Hyperfilm ECL; Amersham Biosci-
ences, Little Chalfont, UK).
 Statistical Analysis and Software 
 Statistical analysis was performed using Student’s t test for un-
paired samples; means were considered statistically significant 
when the p value was  ! 0.05. The Origin computer program (Mi-
crocal Software, Inc., Northampton, Mass., USA) was used to gen-
erate graphs and for statistical analysis.
 Results 
 Expression of SSTR1 and SSTR2 mRNA in the 
Embryonic and Postnatal Mouse Cochlea 
 RT-PCR and the use of specific primer sets indicated 
that SSTR1 and SSTR2 mRNA were detected in the OCs 
from WT mice at E14, E17, and postnatal day (P) 0, P5, 
P10, P14, and P21. A single band of the correct size was 
observed for every tissue, indicating the presence of both 
SSTR1 and SSTR2 mRNA in the OC throughout postna-
tal development. The amplification of   -actin confirmed 
that cDNA synthesis was successful ( fig.  1 ). We per-
formed real-time PCR to determine the quantitative gene 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
1:
48
:4
3 
AM
 Bodmer/Brand/Radojevic
 
Dev Neurosci 2012;34:342–353346
expression of SSTR1 and SSTR2 at E14 and E17. Cochlear 
expression of both genes was significantly increased at 
E17 compared with E14 ( fig. 2 ).
 Embryonic Expression of SSTR1 and SSTR2 
 SSTR1 and SSTR2 were not detected in the embryon-
ic cochlea before E14 (data not shown). At E14, both 
SSTR1 and SSTR2 appeared to be associated with the 
thickened epithelial cells located in KlO ( fig. 3 ). SSTR1 
and SSTR2 immunoreactivity was clearly detected at E17 
in the region of HCs and supporting cells along the length 
of the cochlear duct, which in this stage have become ar-
ranged into the characteristic pattern for the OC ( fig. 4 ). 
Antibody against Hes5 was used as a cochlear develop-
mental marker, and was colocalized with SSTR2 in the 
embryonic OC at E17 ( fig. 4 g).
 Postnatal SSTR1 and SSTR2 Expression (P0–P21) 
 At birth, within the OC, SSTR1 and SSTR2 labeling 
included the IHC, OHC, and DC, extending laterally to 
include the Claudius cells ( fig. 5 d, e). Cochlear tissue was 
largely differentiated by P5 ( fig. 5 f, g). During this period, 
the immunolabeling of the examined SSTR1 and SSTR2 
continued to differentiate in different OC structures. At 
P10, the levels of both SSTR1 and SSTR2 were decreased 
in the IHC, but were high in the OHC, DC, and PiC 
( fig. 6 a, b). At P14, the strongest expression of both recep-
tors was observed in the IHC, OHC, and DC in the OC 
( fig. 6 c, d). By P21, expression of both receptors was less 
strong in the IHC and OHC, and absent in the PiC ( fig.
6 e, f).
242 bp
242 bp
M E14 E17 ntc ntcM P0 P5 P10 P14 P21 Br
M E14
SSTR1 190 bp
SSTR2 242 bp
E17 ntc ntcM P0 P5 P10 P14 P21 Br
320 bp
190 bp
190 bp
-Actin 208 bp
-Actin 208 bp
190 bp
 Fig. 1. Gene expression of SSTR1 and 
SSTR2 in OC explants at different embry-
onic and postnatal ages. SSTR1 and SSTR2 
mRNA were detected in the OC of WT 
mice by RT-PCR and the use of specific 
primer sets at E14 and E17, as well as at P0, 
P5, P10, P14, and P21. Brain (Br) RNA was 
used as a positive control. Omission of RT-
PCR was used as the no-template control 
(ntc).   -Actin was used to control cDNA 
synthesis. M = Molecular weight marker. 
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 Fig. 2. Cochlear expression of SSTR1 and 
SSTR2 genes in OC explants at E14 and 
E17. The relative distribution of SSTR1 and 
SSTR2 mRNA expression in OC tissue 
from WT mice of different embryonic ages 
was quantified by real-time PCR. GAPDH 
was used as an endogenous control. Re-
sults are expressed as the mean ( 8 SE). 
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 As shown in  figure 7 , the developmental patterns of 
SSTR1 and SSTR2 proteins share some similarities, with 
increased protein expression in the first 2 postnatal weeks 
followed by a moderate decrease in expression around the 
time of airborne hearing.
 Effect of Knocking out SSTR1 and SSTR2 in DKO 
Mice 
 SSTR1 and SSTR2 mRNA were detected in the brain 
and OC WT mice by RT-PCR using specific primer sets. 
SSTR1 and SSTR2 mRNA were not detected in brain 
Kolliker‘s organ
Kolliker‘s duct
c d
e f
g h
H/E
ba
Kolliker‘s duct
c d
e f
g h
H/E
ba
Tectorial membrane
Spiral limbus
(inner ridge)Neuroepithelial
cells
 Fig. 3. Immunolabeling of SSTR1 and SSTR2 in the mouse co-
chlea at E14. Cell nuclei are in blue, SSTR1 and SSTR2 are in red, 
and transcription factor Hes5 is in green.  a  The diagram of em-
bryonic OC source: http://syllabus.med.unc.edu.  b  A light mi-
croscopy image of an E14 mouse head (sagittal section) stained 
with hematoxylin/eosin. The box indicates the cochlea.  c ,  d In 
these immunofluorescence images, SSTR1 and SSTR2 can be ob-
served in KlO and the spiral ganglion (SG).  e–h In these immu-
nofluorescence images, SSTR1 and SSTR2 can be observed in ep-
ithelial cells located in the embryonic cochlear duct. Transcrip-
tion factor Hes5 staining was used as a marker for the embryonic 
cochlea. Scale bar = 50   m. 
 Fig. 4. Immunolabeling of SSTR1 and SSTR2 in the mouse cochlea 
at E17. Cell nuclei are in blue, SSTR1 and SSTR2 are in red, and 
transcription factor Hes5 is in green.  a  The diagram of embryonic 
OC source: http://syllabus.med.unc.edu.  b  A light microscopy im-
age of an E1 mouse head (sagittal section) stained with hematoxy-
lin/eosin. The box indicates the cochlea.  c , d  In these immuno-
fluorescence images, SSTR1 and SSTR2 can be observed in the OC 
and spiral ganglion (SG).  e– h  In these immunofluorescence im-
ages, SSTR1 and SSTR2 can be observed in the OHC and IHC. 
Weak labeling was observed in the supporting cells of the embry-
onic cochlear duct. Transcription factor Hes5 staining was used as 
a marker for the embryonic cochlea. Scale bar = 50   m. 
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samples from DKO mice ( fig.  8 a). Using Western blot-
ting, we were unable to detect bands corresponding to 
SSTR1 and SSTR2 in the protein lysate from DKO co-
chlea ( fig. 8 b). Immunohistochemistry was performed to 
locate SSTR1 and SSTR2 in the adult SSTR1/SSTR2 DKO 
mouse cochlea. No SSTR1 or SSTR2 staining was ob-
served in cochlea from DKO mice, indicating the com-
plete absence of both proteins from the cochlea of this 
mouse model and confirming the specificity of the anti-
body used ( fig. 8 c).
 Total Akt and Phosphorylated Akt in Cochlea from 
WT, SSTR1 KO, and DKO Mice 
 The expression of phospho-Akt and total Akt was as-
sessed in the brain and in OC explants from WT, SSTR1 
KO, and DKO mice. We observed reduced levels of both 
c
d e
f g
a
Deiter‘s cells IHC
OHC
Pillar cells
Auditory nerve fibers
Tectorial membrane
Spiral limbus
(inner ridge)
Claudius cells
b
a b
c d
e f
 Fig. 5. The protein expression pattern of SSTR1 and SSTR2 in the 
mouse cochlea from P0 through P5. Cell nuclei are in blue, and 
SSTR1 and SSTR2 are in red.  a The diagram of OC source: http://
syllabus.med.unc.edu.  b ,  c Negative controls.  d ,  e At P0, SSTR1 
and SSTR2 can be observed in the OHC, the IHC, and the mem-
brane of DC.  f ,  g At P5, both receptors can be detected in the OHC, 
the IHC, DC, and the outer and inner PiC. Scale bar = 50   m ( a–g ). 
 Fig. 6. The protein expression pattern of SSTR1 and SSTR2 in the 
mouse cochlea prior to the onset of hearing (P10–P21). Cell nuclei 
are in blue, and SSTR1 and SSTR2 are in red.  a ,  b At P10, SSTR1 
and SSTR2 are strongly expressed in the supporting cells as PiC. 
The OHC and IHC were also positively labeled.  c ,  d At P14, both 
receptors can be detected in the OHC, the IHC, and the mem-
brane of DC.  e ,  f At P21, the expression of both receptors had de-
creased relative to P14, and labeling was detected in the OHC, the 
IHC, and the membrane of DC. Immunofluorescence microscopy 
images: scale bar = 50   m ( a ,  b ). Confocal microscopy images: 
scale bar = 25   m ( c–f ). 
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BrM E14 E17 P0 P5 P10 P14 P21
-Actin 41 kDa
SSTR1 53 kDa
62 kDa
49 kDa
49 kDa
38 kDa
a
BrM E14 E17 P0 P5 P10 P14 P21
-Actin 41 kDa
98 kDa
62 kDa
49 kDa
38 kDa
b SSTR2 80 kDa
242 bp
M ntc MDKODKOW WBr Br
SSTR1 190 bp SSTR2 242 bp
190 bp
242 bp
190 bp
190 bp190 bp
-Actin 208 bp
M DKOWBr MDKO W Br
SSTR1 53 kDa SSTR2 80 kDa
-Actin 41 kDa -Actin 41 kDa
98 kDa
62 kDa
49 kDa
98 kDa
62 kDa
49 kDa
49 kDa
38 kDa
49 kDa
38 kDa
 Fig. 7. Detection of SSTR1 and SSTR2 in the mammalian cochlea by Western blotting. Western blotting reveals 
that SSTR1 and SSTR2 can be detected in protein extracts from embryonic and postnatal OC. Brain extract was 
used as a positive control, and   -actin levels were used as loading controls. SSTR 1 and SSTR2 contain a num-
ber of glycosylation sites (SwissProt), which may explain their migration at a higher molecular weight than pre-
dicted. M = Molecular weight marker. 
 Fig. 8. SSTR1 and SSTR2 are not detected in SSTR1/SSTR2 DKO 
mice.  a RT-PCR was performed on WT and DKO OC. SSTR1 and 
SSTR2 mRNA were detected in the OC from WT mice, but not in 
the OC from DKO mice. Brain (Br) RNA was used as a positive 
control. Omission of RT-PCR was used as the no-template control 
(ntc).   -Actin was used to control cDNA synthesis.  b Western 
blotting reveals that SSTR1 and SSTR2 proteins can only be de-
tected in protein extracts from brain tissue (positive control) and 
in OC extracts from WT mice, but not in the OC from DKO mice. 
Actin serves as a standard to demonstrate that equal amounts of 
protein have been loaded.  c  Immunohistochemical detection of 
SSTR1 and SSTR2 protein in mouse cochlea. A light microscopy 
image of a mouse cochlea stained with hematoxylin/eosin to dem-
onstrate that DKO cochleae have normal morphology. In the im-
munofluorescence images, SSTR1 and SSTR2 proteins cannot be 
detected in DKO cochleae. Cell nuclei are blue; SSTR1 and SSTR2 
are red. Scale bars = 50   m. M = Molecular weight marker; W = 
wild-type mice. 
C
o
lo
r v
er
si
o
n 
av
ai
la
b
le
 o
n
lin
e
 c 
a b
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
1:
48
:4
3 
AM
 Bodmer/Brand/Radojevic
 
Dev Neurosci 2012;34:342–353350
phospho-Akt and total Akt in both strains of KO mice 
compared with WT mice ( fig. 9 b). Phospho-Akt and to-
tal Akt expression was lower in DKO mice than in 
SSTR1 KO mice ( fig. 9 ).   -Actin was used as a loading 
control.
 Discussion 
 The mRNA expression of SST and its receptor has 
been described in the developing mammalian central 
nervous system  [31] . However, little is known about the 
presence of SSTR subtypes in the developing mammalian 
cochlea. The present study was undertaken to investigate 
the expression and the time course of SSTR1 and SSTR2 
in the cochlea of fetal and postnatal mice. We analyzed 
these two individual SSTR subtypes using three indepen-
dent techniques: mRNA analysis using RT-PCR and real-
time PCR, and protein analysis using immunohisto-
chemistry and Western blotting.
 During maturation of the hearing organ, SSTR1 and 
SSTR2 were expressed in cochlea during late embryonic 
development. SSTR1- and SSTR2-positive cells can be 
observed in fetal mice as early as E14, and become present 
in all principal neurosensory cochlear cells before birth. 
The immunoreactivity of both receptors increases until 
approximately P14 (when maximal labeling of the IHC, 
OHC, and supporting cells is reached for both receptors), 
and subsequently decreases by P21.
 Late Embryonic SSTR1 and SSTR2 Expression 
 At E14, the receptors were expressed at the thickened 
epithelial cells located in the embryonic KlO. In mice, the 
cochlear duct develops from the otocyst at approximately 
E11  [2] , and by E12 the growing duct becomes obvious as 
it begins to coil. By E17, HCs and supporting cells along 
the length of KlO have become arranged into the charac-
teristic pattern for the OC  [32] . Cochlear extension and 
coiling will continue until approximately E19–P0. Dur-
ing this period of development, the expression of both 
receptors increased and continued throughout the matu-
ration of OC. We hypothesize that the high expression of 
both receptors at E17 supports the differentiation of the 
neuroepithelial cells in the embryonic OC, as well as gen-
eral growth and development of the inner ear.
 STTR1 and SSTR2 Expression around the Onset of 
Hearing (P0–P14) 
 The next peak of receptor expression occurs at P14 at 
the onset of hearing. SST is also known to modify the 
synapses, and is likely to influence the synaptic activity 
of the inner ear at P14  [33–35] . Like other rodent species, 
mice do not respond to airborne sound shortly after 
birth. The outer ear canal remains closed until P12, and 
auditory brainstem responses cannot be reliably recorded 
before P12–P14  [36–38] . High levels of both SSTR1 and 
SSTR2 proteins are expressed at P14, and were detected 
in supporting cells around the IHC, with weaker expres-
sion in the OHC. The increase of these proteins until P14 
MWM DKOWTBr KO SSTR1
-Actin 41 kDa
pAkt 60 kDa
97 kDa
64 kDa
51 kDa
39 kDa
49 kDa
37 kDa
a
MWM DKOWTBr KO SSTR1 
-Actin 41 kDa
Akt 60 kDa
97 kDa
64 kDa
51 kDa
49 kDa
37 kDa
b
 Fig. 9. Total Akt and phospho-Akt were detected in the OC and brains of SSTR1 KO and DKO mice. Levels of 
both phospho-Akt and total Akt were reduced in SSTR1 KO and DKO mice compared with WT littermates. 
Brain was used as a positive control, and   -actin levels were used as loading controls. MWM = Molecular weight 
marker. 
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may be necessary for the growth and development of the 
OC, although not for mature hearing. Interestingly, there 
is a strong correlation of mRNA and protein levels for 
both receptors, suggesting that SSTR expression in the 
inner ear is controlled at the transcriptional level. In ad-
dition, it is noteworthy that the developmental pattern of 
SSTR1 and SSTR2 expression are similar. In our previous 
publication we observed that deletion of one receptor 
subtype was compensated by an overexpression of the 
other receptor subtype  [25] . These findings support the 
idea that both receptors have a related function in the in-
ner ear.
 After P14, major anatomical structures and connec-
tions are already present. The expression of SSTR1 and 
SSTR2 at P21 is decreased relative to P14. From P21 on-
wards, SSTR1 and SSTR2 were concentrated in the OHC, 
IHC, and their supporting cells. The distribution pat-
terns of SSTR1 and SSTR2 at P21 were similar to those 
observed in adult mice after airborne hearing ability had 
commenced. In our previous study, we demonstrated 
that, in the adult cochlea, SSTR1 and SSTR2 are ex-
pressed in the IHC and OHC of the OC, as well as in de-
fined supporting cells  [25] .
 According to different studies we know that the devel-
opment of the nervous system requires the coordinated 
expression of many complex factors, in which SST seems 
to play an active role. From brain studies it is suggested 
that the SSTR1 and SSTR2 appear relatively early in the 
development. It has been suggested that during brain de-
velopment SST may be involved in synaptogenesis, pro-
liferation, axon pathfinding, and/or as a trophic factor 
 [39, 40] . The expression patterns of SSTR1 RNA in the 
hippocampus and SSTR2 as well as SSTR1 RNA in the 
cerebellum change significantly between E12 and P5. The 
temporal expression of the mRNAs coincides with the 
peak immunoreactivity found for SST by E18 and around 
the time of birth  [21, 41] . These results suggest that SSTR1 
and SSTR2 are closely related to the neurogenesis of the 
hippocampus and cerebellum. SSTR1 and SSTR2 show 
high expression levels at E17. This may suggest that SSTR1 
and SSTR2 serve as trophic factors and play a role in pro-
liferation. Furthermore because of a high expression lev-
el of SSTR1 and SSTR2 at age P14 they may not only be 
involved in proliferation but also in synaptogenesis. 
There are 5 subtypes of SSTR (SSTR1–5). A possible ex-
planation for the lack of dramatic effect on morphology 
of SSTR1/SSTR2 DKO mice is that the other subtypes 
(SSTR3–5) compensate for the absence of SSTR1 and 
SSTR2. Indeed, there is evidence that SST significantly 
contributes to the regulation of the expression of its re-
ceptors (especially for the SSTR2  [42] ). Furthermore, in 
SST KO and SSTR1 KO mice, brain levels of SSTR, and 
in particular of the SSTR2, are upregulated  [43] . No mor-
phological evidence was found by the lack of SSTR1 and 
SSTR2 expression in the central nervous system region of 
KO mice  [29, 43–46] .
 Protecting the Inner Ear 
 The retina and ear share common characteristics. 
Both the retina and the inner ear arise from neuroepi-
thelium, and both harbor sensitive sensory cells together 
with supporting cells. Both organs display a complex and 
highly organized microarchitecture. Therefore, the mo-
lecular events involved in damage and death of HCs 
might also share similar features to those involved in ret-
inal cell damage and death  [47, 48] . Some aspects of the 
developmental patterns of the somatostatinergic system 
in the retina, including early SST expression, the pres-
ence of transient expressing ganglion cells, and observa-
tions in SSTR KO mice, clearly indicate that this peptide 
has a variety of roles in retinal development  [49–53] . 
Moreover, SSTR2 activation by SST or its analogues can 
protect retinal neurons against ischemia-induced dam-
age  [13] , and studies in mice with genetic alterations of 
the somatostatinergic system have revealed that an in-
creased presence of functional SSTR2 protects against 
retinal ischemia  [54] . Therefore, SSTR2 analogues may 
be of therapeutic benefit in retinal diseases such as glau-
coma or diabetic retinopathy, but may also protect from 
hearing loss due to HC degeneration and death. Research 
suggests that SST is involved in cell survival. In mouse 
retinal explants, SSTR2 has been shown to inhibit potas-
sium-induced glutamate excitotoxicity  [34] . Gentamicin 
and cisplatin are widely used pharmacological agents 
that may induce irreversible hearing loss. Both drugs 
damage mainly HCs, resulting in apoptotic HCs death 
 [55, 56] . Our group has demonstrated that SST can pro-
tect against aminoglycoside toxicity in a dosage-depen-
dent manner in vitro  [57] . Therefore, we hypothesized 
that the somatostatinergic system within the cochlea 
may have neuroprotective properties. These receptors 
may be employed as therapeutic agents to treat damage 
to and/or illness of the auditory system. Identification 
and characterization of the receptors and knowledge of 
peptide functions in cochlear development could enable 
us to design a peptide-based therapeutic strategy. Genta-
micin exposure also activates pathways that promote HC 
survival in agreement with the current opinion that cells 
exist in a finely tuned balance between survival and cell 
death  [58–60] . Some survival pathways that operate in 
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HCs, such as the H-Ras/Raf/MEK/Erk pathway and the 
PI3K-Akt pathway, have been defined  [61] . An interest-
ing publication by Chung et al.  [58] demonstrated that 
PI3K/Akt mediates HC survival and opposes gentamicin 
toxicity in neonatal rat OC explants. We therefore asked 
whether the observed protection from gentamicin by 
SST might be due to the influence of SST on the PI3K/
Akt pathway. There are some reports in the literature 
linking SST on the PI3K/Akt pathway. Furthermore, the 
activity of the PI3K/Akt pathway was altered by SST in 
pituitary tumor cells  [38] , and we have recently shown 
that the PI3K/Akt pathway is involved in NF-  B-depen-
dent HC survival  [39] . Indeed, data collected from our 
analysis of levels of phospho-Akt and total Akt protein 
in WT, SSTR1 KO, and DKO mice demonstrated that 
deletion of the receptors results in reduced levels of phos-
pho-Akt and total Akt in the KO mice compared with 
WT mice ( fig. 8 ). Therefore, we can speculate that the 
protection observed by SST on gentamicin-induced HC 
loss is due to the influence of SST at the PI3K/Akt path-
way. Another possibility might be that SST protects HCs 
from aminoglycoside toxicity-induced cell death by its 
ability to limit glutamate release or to inhibit glutamate 
excitotoxicity, which has already been observed in the 
retina  [34] .
 One family of growth factors, the neurotrophins, plays 
diverse roles in the survival of cochlear neurons. HCs are 
thought to secrete bone-derived neurotrophic factor and/
or neurotrophin-3 and attract nerve fibers to form syn-
apses  [40, 41] . These developmental and protective func-
tions also apply to SST.
 Finally, future investigations in the development of the 
inner ear should concentrate on the time at which air-
borne hearing ability commences. A peak in the expres-
sion of certain receptors is observed at this time, when the 
auditory pathways have achieved their final organization, 
suggesting that SST and its receptors may operate (or co-
operate) during cochlear development. Additional stud-
ies are needed to clarify to what extent SSTR play an es-
sential role during the development of cochlear neural 
structures, and which transduction mechanisms are in-
volved given the activation of specific SSTR subtypes.
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